<DOC>
	<DOCNO>NCT02403544</DOCNO>
	<brief_summary>This phase I study evaluate safety concurrent chemoradiation combine radiotherapy ( IGRT ) two cytotoxic agent , capecitabine oxaliplatin patient advance inoperable hepatocellular carcinoma .</brief_summary>
	<brief_title>Phase I Study Image-Guided Radiation Concurrent With Double-Agent Chemotherapy Hepatocellular Carcinoma</brief_title>
	<detailed_description>In phase I study , patient advance inoperable hepatocellular carcinoma , fail strategy recruit . The primary tumor nearby metastatic node irradiate Image-Guided Radiation Therapy ( IGRT ) mostly conventional fraction . During course , oral capecitabine intravenous oxaliplatin give concurrently . The maximum tolerated dose ( MTD ) two drug determine escalation accord occurrence dose limit toxicity ( DLT ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Criteria : KPS≥80 . Life expectancy≥16 month . Histopathologically clinically diagnose HCC . BarcelonaClinic Liver Cancer ( BCLC ) 0C without distant metastasis . The primary tumor unresectable , inoperable fail previous therapy . Childpugh≤6 ( Child A ) , Indocyanine green retention rate 15min &lt; 20 % . HGb≥100g/L , WBC≥3×109/L , NEUT≥1.5×109/L , PLT≥75×109/L , Creatine≤1.5mg/dl ( UNL ) , Bun≤30mg/dl , Alanine aminotransferase/Aspartate aminotransferase/Alkaline phosphatase≤2.5×UNL , TBil≤1.5×UNL , Prothrombin time≤1.5×UNL , INR≤1.5 . No prior liver upper abdomen radiation therapy . No previous history allergic reaction attribute fluorouracil platinum drug . Be conscious could cooperate comply protocol study , simulation , smooth breathe position radiotherapy . Be ready follow . Fulfill dosages requirement target dose limit organ risk . The patient antihepatitisvirus therapy indicate . Sorafenib discontinue 7 day start irradiation . Subjects informed diagnosis advance HCC fully inform content study investigator use write consent form , give write consent participate study free . KPS≤70 . Existing distant metastasis . ChildPugh≥7 , Indocyanine green retention rate 15min ≥20 % . Primary tumor within liver irradiate . Past liver transplantation . Complications cirrhosis : active gastrointestinal bleeding , hepatic encephalopathy , refractory ascites , peritonitis , hepatorenal syndrome , hepatopulmonary syndrome . Upper gastrointestinal bleeding within 3 month . Any carcinoma , except cure nonmelanoma skin carcinoma , treat insitu cervical cancer ≤T1 bladder cancer . After plan optimization , physician still consider risky treat patient plan benefit negligible . Not conscious cooperate comply protocol study . Previous history allergic reaction attribute fluorouracil platinum . Patients serious comorbidities uncontrolled medical condition investigator feel might compromise study participation ( include limit : myocardial infarction , congestive heart failure ( NYHA &gt; 2 ) , unstable angina , active cardiomyopathy , unstable ventricular arrhythmia , uncontrolled psychotic disorder , uncontrolled hypertension cerebrovascular disease previous stroke within 6 month , serious infections，positive HIV test , poorly control diabetes mellitus fast bloodglucose &gt; 8mmol/L 2hour postprandial blood glucose &gt; 11mmol/L within past month ) . Thrombolytic therapy within 4 week , concurrent anticoagulant therapy . Pregnant , nursing , possibly pregnant woman , woman desire become pregnant study period . Participation investigational study within 4 week precede start study treatment . Other case judge investigator ineligible participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Clinical Trial , Phase I</keyword>
	<keyword>Concurrent Chemoradiation</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Carcinoma , Hepatocellular</keyword>
</DOC>